C. Reynolds
About
C. Reynolds is a scholar working on Oncology, Hematology and Genetics.
According to data from OpenAlex, C. Reynolds has authored 23 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Hematology and 6 papers in Genetics. Recurrent topics in C. Reynolds's work include Hematopoietic Stem Cell Transplantation (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). C. Reynolds is often cited by papers focused on Hematopoietic Stem Cell Transplantation (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). C. Reynolds collaborates with scholars based in United States, Germany and Switzerland. C. Reynolds's co-authors include Voravit Ratanatharathorn, Joseph P. Uberti, Lois Ayash, James L.M. Ferrara, Pavan Reddy, Samuel Silver, Michael A. Becker, Thomas Braun, S. Silver and Maya Guglin and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Arthroplasty.
In The Last Decade
C. Reynolds
22 papers receiving 540 citations
Peers
C. Reynolds
Abraham Avigdor Israel
Brit B. Turnbull United States
Maricer P. Escalón United States
JR Schriber United States
Jolanta B. Perz Germany
MR Litzow United States
Jacques Olivier Bay France
Celina Ledesma United States
Indu Lal United States
H Hagberg Sweden
Citations per year, relative to C. Reynolds C. Reynolds (= 1×)
peers
Abraham Avigdor
Countries citing papers authored by C. Reynolds
Since
Specialization
Citations
This map shows the geographic impact of C. Reynolds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Reynolds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Reynolds more than expected).
Fields of papers citing papers by C. Reynolds
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by C. Reynolds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Reynolds. The network helps show where C. Reynolds may publish in the future.
Co-authorship network of co-authors of C. Reynolds
This figure shows the co-authorship network connecting the top 25 collaborators of C. Reynolds. A scholar is included among the top collaborators of C. Reynolds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Reynolds. C. Reynolds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lee, Ha Eun, et al.. (2023). Verbal autopsy analysis of maternal mortality in Bong County, Liberia: a retrospective mixed methods study. BMJ Open Quality. 12(2). e002147–e002147.
2.
Issa, Tariq Z., Yunsoo Lee, Mark J. Lambrechts, et al.. (2023). Publication rates of abstracts presented across 6 major spine specialty conferences. North American Spine Society Journal (NASSJ). 14. 100227–100227.
3.
Reynolds, C., Tariq Z. Issa, & David W. Manning. (2023). Patients Who Have Pre-Existing Atrial Fibrillation Require Increased Postoperative Care Following Total Joint Arthroplasty. The Journal of Arthroplasty. 39(1). 60–67.
4.
Reynolds, C., et al.. (2023). Factors Associated with Presentation of Severe Adolescent Idiopathic Scoliosis. Journal of the Pediatric Orthopaedic Society of North America. 5(3). 651–651.
5.
Reynolds, C., Tariq Z. Issa, & David W. Manning. (2023). Patients Who Have a Prior History of Pulmonary Embolism Require Increased Postoperative Care Following Total Joint Arthroplasty. The Journal of Arthroplasty. 39(5). 1245–1252.
6.
Andorsky, David, Morton Coleman, Abdulraheem Yacoub, et al.. (2020). INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL). Hematology Transfusion and Cell Therapy. 42. 222–222.
7.
Rummel, Mathias, David Andorsky, Morton Coleman, et al.. (2019). PS1253 MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION #R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. HemaSphere. 3(S1). 572–572.
8.
Sharman, Jeff P., Morton Coleman, Abdulraheem Yacoub, et al.. (2019). INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. Hematological Oncology. 37(S2). 115–116.
9.
Herbst, Roy S., Mary W. Redman, Edward S. Kim, et al.. (2017). Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet Oncology. 19(1). 101–114.
10.
Reynolds, C., Alexander I. Spira, William Larry Gluck, et al.. (2011). Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients.. Journal of Clinical Oncology. 29(15_suppl). 7549–7549.
11.
Guglin, Maya, Gregory Hartlage, C. Reynolds, Chen Ren, & Vinod F. Patel. (2009). Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study. Journal of Cardiac Failure. 15(8). 651–657.
12.
Jotte, Robert M., Paul Conkling, C. Reynolds, et al.. (2009). 9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial. European Journal of Cancer Supplements. 7(2). 540–541.
13.
Reynolds, C., Dennis Vu, Robert M. Jotte, et al.. (2007). An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 7610–7610.
14.
Reddy, Pavan, K J Johnson, Joseph P. Uberti, et al.. (2006). Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 38(5). 351–357.
15.
Uberti, Joseph P., Lois Ayash, Voravit Ratanatharathorn, et al.. (2005). Pilot Trial on the Use of Etanercept and Methylprednisolone as Primary Treatment for Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 11(9). 680–687.
16.
Reynolds, C., John E. Levine, Joseph P. Uberti, et al.. (2005). Keratinocyte growth factor (palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host-disease (AGVHD) in patients at high risk of AGVHD. 3. 78–79.
17.
Uberti, Joseph P., Lois Ayash, T. Braun, et al.. (2004). Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplantation. 34(5). 425–431.
18.
Ratanatharathorn, Voravit, Lois Ayash, C. Reynolds, et al.. (2003). Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biology of Blood and Marrow Transplantation. 9(8). 505–511.
19.
Levine, John E., Joseph P. Uberti, Lois Ayash, et al.. (2003). Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy. Biology of Blood and Marrow Transplantation. 9(3). 189–197.
20.
Clarke, Michael F., S. Silver, Thomas Braun, et al.. (2001). Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review. Bone Marrow Transplantation. 27(9). 939–947.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Abraham Avigdor Breakdown of academic impact, for papers by Brit B. Turnbull Breakdown of academic impact, for papers by Maricer P. Escalón Breakdown of academic impact, for papers by JR Schriber Breakdown of academic impact, for papers by Jolanta B. Perz Breakdown of academic impact, for papers by MR Litzow Breakdown of academic impact, for papers by Jacques Olivier Bay Breakdown of academic impact, for papers by Celina Ledesma Breakdown of academic impact, for papers by Indu Lal Breakdown of academic impact, for papers by H Hagberg